Semapimod

Star0

DB12094InvestigationalSmall molecule

Semapimod has been used in trials studying the treatment of Crohn Disease.

Mechanism: Pharmacologically active on Mitogen-activated protein kinase 14
Curator reviewed
Formula / weight: C₃₄H₅₂N₁₈O₂ · 744.914 g/mol (avg)
Code names: CPSI-2364 FREE BASE

Resolves to

Compound

UNII9SGW2H1K8PCAS352513-83-8ChEMBLCHEMBL2107779PubChem5745214

Structure

InChIKeyPWDYHMBTPGXCSN-VCBMUGGBSA-NSMILESC\C(=N/NC(N)=N)C1=CC(=CC(NC(=O)CCCCCCCCC(=O)NC2=CC(=CC(=C2)C(\C)=N\NC(N)=N)C(\C)=N\NC(N)=N)=C1)C(\C)=N\NC(N)=N

Targets

Q16539MAPK14P04049RAF1

What you can answer from here — as of August 30, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Semapimod, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account